Thursday, 18 Oct 2018

You are here

It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk

Evidence from multiple studies suggests there is an increased risk of lymphoma in rheumatoid arthritis (RA) that is believed to be linked to the cumulative activity of the disease.  

It is also debated whether  biologic and non-biologic treatments increase this risk. Rheumatoid arthritis (RA) patients showed to have higher incidence of diffuse large B –cell lymphoma (DLBCL) unrelated to biologic therapy. There is very little data on lymphoma risk in non-TNF biologic treatment groups.

Possible association between use of methotrexate and EBV-positive lymphoproliferative disorders was reported; as well as increased risk of lymphoma in TNF-treated Crohns’ patients was reported prior.

A collaborative analysis of twelve European biologic registers from nine countries aimed to study if there might be a switch in the subtype distribution of lymphomas in RA linked to specific antirheumatic treatments.

Among close to 125,000 registry patients, 533 developed lymphomas. Multiple steps were taken to analyze the spectrum of lymphoma subtypes.

No significant differences in the distribution of Hodgkins lymphoma (HL) versus B-NHL versus T-NHL between patients who were either bionaïve or TNFi-treated..

After standardizing by age, the distribution of HL versus B-NHL versus T-NHL observed in the RA group was comparable to that seen in the  general population.

Within the B-NHL subtype, however, DLBCL was significantly higher in RA compared with the general population (56% of all B-NHL in RA vs 30% in the general population); whereas CLL was significantly less frequent (16% of all B-NHL in RA vs 38% in the general population).

Only six, six and three lymphomas occurred in patients treated with rituximab, tocilizumab and abatacept, respectively, at lymphoma diagnosis. As a result, authors were not able to analyze data in non-TNF group due to small sample size.

It has been pointed out that the comparison between the treatment groups might be affected by age difference, since the age is an important factor in lymphogenesys.

Authors could not analyze any potential influence of additional therapies with MTX or other conventional synthetic DMARDs.

In general, the analysis supported the conclusion that the risk of lymphoma in RA is more dependent on RA itself and especially the disease activity than on the RA treatment; the spectrum of lymphoma subtypes seems not to be altered by TNFi.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).

Biomarker Combo Predicts TNF Inhibitor Responses

Based on clinical trial data, patients starting tumour necrosis factor-alpha inhibitors (TNFi) have roughly a two-thirds chance of achieiving a good clinical response. French investigators have studied a series of potential biomarkers and surmised that the combination of baseline prealbumin, platelet factor 4 and S100A12 can predict a 78% response to TNFi in rheumatoid arthritis (RA) patients.

TNF Inhibitors Don't Increase Cancer Risk in Children

While the risk of neoplasia with tumour necrosis factor inhibitor (TNFi) use has been largely nullified in most inflammatory disorders, this risk in children is less certain. However a recent study shows no risk of increased cancer in children treated with TNFi for juvenile idiopathic arthritis (JIA), pediatric inflammatory bowel disease (pIBD) and pediatric plaque psoriasis (pPsO).

Risk of Psoriasis Complicating TNF Inhibitor Therapy

A population-based study of claims data from Korea shows that among inflammatory bowel disease (IBD) patients receiving tumour necrosis factor inhibitors (TNFi) there is a 3.7 per 100 patient-year risk of paradoxically developing psoriasis - a rate that is roughly 3-fold higher than risk in TNFi-naive IBD patients.

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population.